Readjust C-Suite and Board Compensation

Discussion in 'Acorda Therapeutics' started by anonymous, Jun 30, 2019 at 3:15 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    ACOR is done. This place will plummet further due to poor decisions by ego-maniacs!
    Everyone is out looking!! It is a poor place to work with no future. Overpaid fools run this place. Sales leadership is a joke!! BW? SM? Shitty overgrown boys and gals (DMs)............Jesus! Ya'll just let losers float around here! We are all looking to leave.
     

  2. anonymous

    anonymous Guest

    Let's hope you are incorrect.

    Lots of good people work in Acorda Therapeutics; plus, Inbrija is a much needed bridge for patients experiencing frequent and debilitating OFF episodes.

    But the Board needs some gonads to make changes in the Leadership structure who are currently repeating their Ampyra experience :: their only Launch experience :: and hoping for success. Furthermore, Acorda has an over compensated C-Suite who has grown dependent of their fat packages and may not be looking for Investors best interest. Otherwise, this company should have been sold a year back when Scopia strongly made the suggestion, and the stock value was in the 30s.

    MAGA
    Make Acorda Great Again
     
  3. anonymous

    anonymous Guest

    same old crap !!!!!!!!!!!
    C-Suite is NOT over compensated !! in fact a case can be made that they are well underpaid ! the Board knows that.

    The company stock price was never worth $40+/-. That was a mirage !! So don't blame the Leadership for the effect of gravity on the shareprice !!
     
  4. anonymous

    anonymous Guest


    Same old manipulation of the facts that is so easy to debunked with a simple GOOGLE search:

    Dec 19, 2014 to Jan 16, 2015; ACOR ranged from 40.06 to 42.59

    Dec 31, 2015 to Jan 8, 2016; ACOR ranged from 42.98 to 40.22

    Back then, Andy Blight and Tony Caggiano were the Heads of Development and make sure that the Pipeline positively progress.
     
  5. anonymous

    anonymous Guest

    Not crap... fact... your an ass

    Closed 42.65 on 12-24-15
    No mirage . That’s a real #
    Down 85% since then
    CEO responsible for performance....Who do you blame... Habib???

    On thing for sure is That you are certainly overpaid for whatever it is you think you do here. Likely you lost out on all job opportunities your smarter peer took from you when they left.

    So live in your mirage.... when your scraping bottom and worrying about layofff or a fire sale at $8 a share... don’t worry, just tell yourself it’s a mirage.
     
  6. anonymous

    anonymous Guest

    Just a reminder....actual price vs. 'worth' are two completely different entities.: ACOR was priced as high as you say. However it was not 'worth' that amount. A highly inflated biopharma buying spree jacked up many corporate shareprices way beyond their worth (ie actual EPS not the inflated projections of the biopharma shills on the Street). You must honestly know that is the case. The individuals you note were good troopers but simply did not have the 'right stuff' to implement the pipeline they envisioned. Not saying the current crew is any better...just different !

    As far as compensation, agree you have a point, they may be overpaid to some degree; however, the Board determines that, not rank&file (us).

    Lets keep Inbrija sales rocketing up so we can get a true growth in share price based on reality not the hype of shills.

    Habib is probably a mouthpiece for the C-Suite.
     
  7. anonymous

    anonymous Guest


    THUMBS UP TO YOUR COMMENT
    Finally, someone that speaks reasonably, fair & balanced.

    On Drs Blight & Caggiano, they did built a pipeline, which is much more than the current Head of Development, Dr Blank, & Business Development, recently departed Hindman, have done. So "just different" does not equate to parity in accomplishments.
     
  8. anonymous

    anonymous Guest

    True, they did more than the recent pair.
     
  9. anonymous

    anonymous Guest

    We should bring back Augusto. He was great. We all loved him in Marketing. He did an amazing job building up the pipeline. Where is he now?
     
  10. anonymous

    anonymous Guest

    Now a regional marketing director at Pfizer,
     
  11. anonymous

    anonymous Guest

    no, the VP Med Affairs in Latin America for Merck and enjoying the stress-free work environment.
     
  12. anonymous

    anonymous Guest

    Headquarters in Caracas Ven. Not that stress free!!! LMAO you dum ass!!
     
  13. anonymous

    anonymous Guest

    Bet he is doing much better than those Mexicans that used to report to him.
    Heard that they have been taken into custody by ICE and are currently waiting to be deported.

    BTW, today we closed at 6.89 with a Market Cap of 331M.
    Great accomplishment, right???!!!
     
  14. anonymous

    anonymous Guest

    That's known as the inflection point !! We are on a major rebound!
     
  15. anonymous

    anonymous Guest

    Habib, being down 70% and struggling to stay above $5/share doesn’t qualify as a rebound anywhere other than your Pravda like PR firm.
     
  16. anonymous

    anonymous Guest

    UP BIG TIME TODAY !!! Over 1.20% already !!!!!!
     
  17. anonymous

    anonymous Guest

    Not true at all. One of them lives right next to Mar-o-Lago and regularly has drinks with POTUS; and the other lives in some idyllic South Pacific Island sipping Tiki drinks with the local babes. They are rumors of their returns to help us out of this mess, but doubt it.
     
  18. anonymous

    anonymous Guest

    Fake news YOU P O S !!!!
     
  19. anonymous

    anonymous Guest

    Why would anyone leave paradise to come back to a dumpster.. you guys are done... you live with what you launch.. your next quarter will pull the curtain back after your channel stocking $ and reveal the sad truth of NO PULLTHROUGH
     
  20. anonymous

    anonymous Guest

    The astrological analysis is very positive for Aug 6 thru Aug 17. A conjunction of Saturn with Mercury. Expect good things to develop